Progenics Pharmaceuticals (PGNX) Shares are Up 6.37%

Progenics Pharmaceuticals (PGNX) : Traders are bullish on Progenics Pharmaceuticals (PGNX) as it has outperformed the S&P 500 by a wide margin of 29.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.31%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.37% in the last 1 week, and is up 30.98% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 11.81% and the 50-Day Moving Average is 27.48%. Progenics Pharmaceuticals (NASDAQ:PGNX): stock turned positive on Friday. Though the stock opened at $6.67, the bulls momentum made the stock top out at $6.78 level for the day. The stock recorded a low of $6.63 and closed the trading day at $6.68, in the green by 0.15%. The total traded volume for the day was 684,374. The stock had closed at $6.67 in the previous days trading.


The company Insiders own 5.48% of Progenics Pharmaceuticals shares according to the proxy statements. Institutional Investors own 84.82% of Progenics Pharmaceuticals shares.

Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.